RxDoctor Payments Data

Bankim Shah, MD

Internal Medicine · Toms River, NJNPI 1609899632

Payments from drug & device makers

$1,203in general payments, 2019–2025

Across 51 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$408
  • GSK$161
  • Boston Scientific$132
  • AbbVie$125
  • Biohaven Pharmaceuticals, Inc.$125
  • Gilead$58
  • plus $193 from 9 others

What the payments were for

  • Food & beverage$1,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,203 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$48,292
Medicare patients
146
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl29$32,135
EliquisApixaban37$30,937
JanuviaSitagliptin Phosphate18$28,154
FarxigaDapagliflozin Propanediol25$22,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,862
OzempicSemaglutide14$16,674
Atorvastatin Calcium183$1,596
Levothyroxine Sodium131$1,437
Losartan Potassium120$1,226
Valsartan30$1,152
Metoprolol Succinate84$1,113
Albuterol Sulfate HfaAlbuterol Sulfate26$1,031
Rosuvastatin Calcium46$1,014
Irbesartan22$911
SynthroidLevothyroxine Sodium19$901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$30,93737 claims
AstraZenecaFarxiga$28$22,73725 claims
GSKTrelegy Ellipta$161$16,86219 claims
Novo NordiskOzempic$408$16,67414 claims
AbbVieSynthroid$125$90119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →